12 Month Price Forecast For GMED
Distance to GMED Price Forecasts
GMED Price Momentum
🤔 Considering Globus Medical (GMED)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 3:14 AM UTC
GMED Analyst Ratings & Price Targets
Based on our analysis of 21 Wall Street analysts, GMED has a bullish consensus with a median price target of $100.00 (ranging from $85.00 to $115.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $83.93, the median forecast implies a 19.1% upside. This outlook is supported by 10 Buy, 5 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Wittes at Roth MKM, projecting a 37.0% upside. Conversely, the most conservative target is provided by William Plovanic at Canaccord Genuity, suggesting a 1.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GMED Analyst Consensus
GMED Price Target Range
Latest GMED Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GMED.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 6, 2025 | Needham | David Saxon | Hold | Reiterates | $0.00 |
| Jan 10, 2025 | Canaccord Genuity | William Plovanic | Buy | Maintains | $101.00 |
| Jan 9, 2025 | B of A Securities | Craig Bijou | Neutral | Upgrade | $97.00 |
| Jan 9, 2025 | Needham | David Saxon | Hold | Reiterates | $0.00 |
| Dec 18, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $90.00 |
| Dec 17, 2024 | Roth MKM | Jason Wittes | Buy | Maintains | $115.00 |
| Dec 12, 2024 | BTIG | Ryan Zimmerman | Buy | Maintains | $91.00 |
| Dec 11, 2024 | Wells Fargo | Vik Chopra | Overweight | Maintains | $95.00 |
| Dec 9, 2024 | Canaccord Genuity | William Plovanic | Buy | Maintains | $92.00 |
| Dec 2, 2024 | Morgan Stanley | Drew Ranieri | Overweight | Upgrade | $100.00 |
| Nov 11, 2024 | Morgan Stanley | Drew Ranieri | Equal-Weight | Maintains | $83.00 |
| Nov 7, 2024 | Needham | David Saxon | Hold | Reiterates | $0.00 |
| Nov 6, 2024 | Wells Fargo | Vik Chopra | Overweight | Maintains | $88.00 |
| Nov 6, 2024 | Stifel | Mathew Blackman | Buy | Maintains | $92.00 |
| Nov 6, 2024 | Canaccord Genuity | William Plovanic | Buy | Maintains | $85.00 |
| Nov 6, 2024 | Needham | David Saxon | Hold | Reiterates | $0.00 |
| Nov 6, 2024 | RBC Capital | Shagun Singh | Outperform | Maintains | $92.00 |
| Nov 6, 2024 | Roth MKM | Jason Wittes | Buy | Reiterates | $100.00 |
| Nov 6, 2024 | B of A Securities | Craig Bijou | Underperform | Maintains | $80.00 |
| Nov 6, 2024 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $100.00 |
Stocks Similar to Globus Medical Inc
The following stocks are similar to Globus Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Globus Medical Inc (GMED) Financial Data
Globus Medical Inc has a market capitalization of $11.43B with a P/E ratio of 135.4x. The company generates $2.48B in trailing twelve-month revenue with a 3.7% profit margin.
Revenue growth is +63.1% quarter-over-quarter, while maintaining an operating margin of +17.7% and return on equity of +2.2%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Globus Medical Inc (GMED) Company Overview
About Globus Medical Inc
Develops medical devices for musculoskeletal disorders.
The company generates revenue by developing and selling a range of medical devices for spine and orthopedic trauma, including implants, biologic products, and surgical solutions. It sells these products through direct sales, distributor representatives, and independent agents, targeting healthcare providers and institutions both in the U.S. and internationally.
Founded in 2003 and headquartered in Audubon, Pennsylvania, Globus Medical focuses on innovative solutions for treating various musculoskeletal conditions, including degenerative diseases and traumatic injuries. Their product offerings include advanced motion preservation technologies and regenerative biologic products, positioning the company as a significant player in the medical device industry.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
5,000
CEO
Mr. Daniel T. Scavilla
Country
United States
IPO Year
2012
Website
www.globusmedical.comGlobus Medical Inc (GMED) Latest News & Analysis
Globus Medical (GMED) is anticipated to report strong earnings, with key factors suggesting a likely earnings beat in its upcoming financial report.
Globus Medical's potential for an earnings beat could signal strong financial health, likely driving stock price appreciation and attracting investor interest.
GMED will acquire all shares of Nevro in an all-cash deal, aiming to create new growth opportunities.
GMED's acquisition of Nevro signals potential for increased market share and revenue growth, which can enhance investor confidence and drive stock value.
Kahn Swick & Foti, LLC is investigating the proposed sale of Nevro Corp. (NVRO) to Globus Medical (GMED), which offers Nevro shareholders $5.85 per share.
The investigation into Nevro's sale to Globus Medical may signal potential issues with the deal's valuation, impacting shareholder confidence and stock prices for both companies.
Globus Medical (NYSE: GMED) will acquire Nevro Corp. (NYSE: NVRO) for $5.85 per share in an all-cash deal valued at approximately $250 million. The agreement is approved by both companies' boards.
Globus Medical's acquisition of Nevro for $250 million at $5.85 per share indicates strategic growth in the musculoskeletal and chronic pain markets, potentially affecting stock performance and market positioning.
Zacks Premium's Style Scores aid value, growth, and momentum investors in identifying strong stocks, enhancing stock selection processes.
The Zacks Style Scores can help investors identify strong stocks across different strategies, potentially improving portfolio performance and investment decisions.
As of February 5, 2025, two healthcare stocks are signaling potential concerns for investors who prioritize momentum in their trading strategies.
Warning signals in healthcare stocks may indicate potential declines, impacting momentum-driven investment strategies and leading to increased volatility in the sector.
Frequently Asked Questions About GMED Stock
What is Globus Medical Inc's (GMED) stock forecast for 2025?
Based on our analysis of 21 Wall Street analysts, Globus Medical Inc (GMED) has a median price target of $100.00. The highest price target is $115.00 and the lowest is $85.00.
Is GMED stock a good investment in 2025?
According to current analyst ratings, GMED has 10 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $83.93. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for GMED stock?
Wall Street analysts predict GMED stock could reach $100.00 in the next 12 months. This represents a 19.1% increase from the current price of $83.93. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Globus Medical Inc's business model?
The company generates revenue by developing and selling a range of medical devices for spine and orthopedic trauma, including implants, biologic products, and surgical solutions. It sells these products through direct sales, distributor representatives, and independent agents, targeting healthcare providers and institutions both in the U.S. and internationally.
What is the highest forecasted price for GMED Globus Medical Inc?
The highest price target for GMED is $115.00 from Jason Wittes at Roth MKM, which represents a 37.0% increase from the current price of $83.93.
What is the lowest forecasted price for GMED Globus Medical Inc?
The lowest price target for GMED is $85.00 from William Plovanic at Canaccord Genuity, which represents a 1.3% increase from the current price of $83.93.
What is the overall GMED consensus from analysts for Globus Medical Inc?
The overall analyst consensus for GMED is bullish. Out of 21 Wall Street analysts, 10 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $100.00.
How accurate are GMED stock price projections?
Stock price projections, including those for Globus Medical Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
